

**GENERAL SERVICES  
ADMINISTRATION**

[OMB Control No. 3090-0221]

**Civilian Board of Contract Appeals;  
Information Collection; Civilian Board  
of Contract Appeals Rules of  
Procedure****AGENCY:** Civilian Board of Contract Appeals, GSA.**ACTION:** Notice of request for comments regarding a revision to an existing OMB clearance.**SUMMARY:** Under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35), the General Services Administration will be submitting to the Office of Management and Budget (OMB) a request to review and approve an extension of a currently approved information collection requirement regarding the Civilian Board of Contract Appeals (CBCA) Rules of Procedure. The clearance currently expires on January 31, 2008.

Public comments are particularly invited on: Whether this collection of information is necessary and whether it will have practical utility; whether our estimate of the public burden of this collection of information is accurate and based on valid assumptions and methodology; and ways to enhance the quality, utility, and clarity of the information to be collected.

**DATES:** Submit comments on or before: January 22, 2008.**FOR FURTHER INFORMATION CONTACT:** Margaret S. Pfunder, Chief Counsel, Civilian Board of Contract Appeals, 1800 F Street, NW., Washington, DC 20405, telephone (202) 606-8800 or via e-mail to [Margaret.Pfunder@gsa.gov](mailto:Margaret.Pfunder@gsa.gov).**ADDRESSES:** Submit comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to the Regulatory Secretariat (VIR), General Services Administration, Room 4035, 1800 F Street, NW., Washington, DC 20405. Please cite OMB Control No. 3090-0221, Civilian Board of Contract Appeals Rules Procedure, in all correspondence.**SUPPLEMENTARY INFORMATION:****A. Purpose**

The CBCA requires the information collected in order to conduct proceedings in contract appeals and petitions, and cost applications. Parties include those persons or entities filing appeals, petitions, cost applications, and government agencies.

**B. Annual Reporting Burden***Respondents:* 55.*Responses Per Respondent:* 1.*Hours Per Response:* .117.*Total Burden Hours:* 6.4.**Obtaining Copies of Proposals:**

Requesters may obtain a copy of the information collection documents from the General Services Administration, Regulatory Secretariat (VIR), 1800 F Street, NW., Room 4035, Washington, DC 20405, telephone (202) 501-4755. Please cite OMB Control No. 3090-0221, Civilian Board of Contract Appeals Rules of Procedure, in all correspondence.

Dated: October 30, 2007

**Casey Coleman,***Chief Information Officer.*

[FR Doc. E7-22603 Filed 11-19-07; 8:45 am]

**BILLING CODE 6820-AL-S****DEPARTMENT OF HEALTH AND  
HUMAN SERVICES****Meeting of the Advisory Committee on  
Blood Safety and Availability****AGENCY:** Department of Health and Human Services, Office of the Secretary.**ACTION:** Notice.**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services is hereby giving notice that the Advisory Committee on Blood Safety and Availability (ACBSA) will hold a meeting. The meeting will be open to the public.**DATES:** The meeting will take place Wednesday, January 9, 2008 and Thursday, January 10, 2008 from 9 a.m. to 5 p.m.**ADDRESSES:** The Westin Washington, DC City Center, 1400 M Street, NW., Washington, DC 20005. Phone: (202) 429-1700.**FOR FURTHER INFORMATION CONTACT:** Jerry A. Holmberg, PhD, Executive Secretary, Advisory Committee on Blood Safety and Availability, Office of Public Health and Science, Department of Health and Human Services, 1101 Wootton Parkway, Room 250, Rockville, MD 20852, (240) 453-8803, Fax (240) 453-8456, e-mail [ACBSA@hhs.gov](mailto:ACBSA@hhs.gov).**SUPPLEMENTARY INFORMATION:** Since the early 1980s there has been a heightened awareness of transfusion and transplantation safety. The formation of the ACBSA directly resulted out of concern regarding infectious diseases and the safety of the blood supply. At this session of the ACBSA, the Committee will discuss further safety developments to enhance transfusion and transplantation safety. These discussions will include the current

landscape and residual risk of known and unknown pathogens. In addition, the Committee will look at needs and barriers to potential opportunities in donor screening and technologies for pathogen reduction.

The public will be given opportunity to provide comments to the Committee on January 9 and 10, 2008. Comments will be limited to five minutes per speaker. Anyone planning to comment is encouraged to contact the Executive Secretary at his/her earliest convenience. Those who wish to have printed material distributed to Advisory Committee members should submit, at a minimum, one copy of the material, to the Executive Secretary prior to close of business January 7, 2008. Likewise, those who wish to utilize electronic data projection to the Committee must submit their materials to the Executive Secretary prior to close of business January 7, 2008.

Dated: November 13, 2007.

**Jerry A. Holmberg,***Executive Secretary, Advisory Committee on Blood Safety and Availability.*

[FR Doc. E7-22653 Filed 11-19-07; 8:45 am]

**BILLING CODE 4150-41-P****DEPARTMENT OF HEALTH AND  
HUMAN SERVICES****Food and Drug Administration**

[Docket No. 2007N-0220]

**Agency Information Collection  
Activities; Submission for Office of  
Management and Budget Review;  
Comment Request; Animal Drug User  
Fee Cover Sheet, FDA Form 3546****AGENCY:** Food and Drug Administration, HHS.**ACTION:** Notice.**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.  
**DATES:** Fax written comments on the collection of information by December 20, 2007.**ADDRESSES:** To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-6974, or e-mailed to [baguilar@omb.eop.gov](mailto:baguilar@omb.eop.gov). All comments should be identified with the OMB control number 0910-0539. Also